Compugen Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.9M 14.09B 3.16B | Sales 2025 * | 35.29M 13.12B 2.95B | Capitalization | 180M 66.89B 15.02B |
---|---|---|---|---|---|
Net income 2024 * | -13M -4.83B -1.09B | Net income 2025 * | -29M -10.78B -2.42B | EV / Sales 2024 * | 4.75 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.1 x |
P/E ratio 2024 * |
-15.5
x | P/E ratio 2025 * |
-7.44
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01/02/01 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01/22/01 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 02/17/02 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11/18/11 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11/18/11 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |